Asset
TENAPANOR HYDROCHLORIDE
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01340053 | phase2 | completed | 2011-05-01 | 2011-12-01 | Ardelyx | A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C) |
| NCT02819687 | phase1 | completed | 2010-11-01 | 2011-03-01 | Ardelyx | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RDX5791 in Healthy Volunteers |
| NCT02796131 | phase1 | completed | 2011-07-01 | 2011-10-01 | Ardelyx | Safety, Tolerability, and Pharmacodynamics of RDX5791 in Healthy Volunteers |
FDA applications (2)
| Application | Type | Applicant |
|---|---|---|
| NDA 211801 | NDA | ARDELYX INC |
| NDA 213931 | NDA | ARDELYX INC |
Marketed products (4)
- IBSRELA
- XPHOZAH
- XPHOZAH
- XPHOZAH